Clinical Trial Update: KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating a KRAS-targeted vaccine in combination with nivolumab and ipilimumab for non-small cell lung cancer. The study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)
• KRAS-targeted vaccine
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING